Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)

NCT07563010 is registered in ClinicalTrials.gov with Center for International Blood and Marrow Transplant Research as lead sponsor.

NCT NCT07563010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)
Lead sponsor
Center for International Blood and Marrow Transplant Research
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
June 30, 2031
Enrollment
146 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, relapsed adult aml, stem cell transplant complications, transplant-related hematologic malignancy